Royal Bank of Canada
PACB icon

Royal Bank of Canada’s Pacific Biosciences PACB Stock Holding History

Royal Bank of Canada’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-300
Closed -$2K – 7092
2019
Q1 		$2K Buy
+300
New +$2.17K ﹤0.01% 6534

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Royal Bank of Canada's PACB Position: Q1 2026 in Review

Royal Bank of Canada reduced its Pacific Biosciences (PACB) stake by 31% in Q1 2026, selling an estimated $13.7K and leaving 17,230 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #5844.

Royal Bank of Canada first reported a position in PACB in Q2 2013 and has held it in 46 quarters since. The position peaked at $2.08M in Q4 2023. 230 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Royal Bank of Canada held 17,230 shares of Pacific Biosciences worth $23K as of Q1 2026.
  • Royal Bank of Canada sold 7,661 Pacific Biosciences shares in Q1 2026, an estimated $13.7K.
  • Pacific Biosciences made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5844 holding.
  • Royal Bank of Canada first reported a position in Pacific Biosciences in Q2 2013 and has held it in 46 quarters since.
  • Royal Bank of Canada's Pacific Biosciences position peaked at $2.08M in Q4 2023.
  • 230 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.